Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment of USD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly...
Trip.com Group's 2026 Lunar New Year Forecast: Longer Journeys and Premium Travel Gain Momentum in the Year of the Horse
Travellers are taking longer trips and venturing further, with cross-border stays of seven nights or more up nearly 40% and long-haul bookings up over 50%. Comfort is becoming a priority, with first-class and business-class flights and five-star...
LG Display showcases wide lineup of world-first, leading OLED monitors
SEOUL, South Korea, Dec. 28, 2025 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, is set to rewrite industry records once again at CES 2026, the world's largest IT and consumer electronics exhibition. LG Display's...
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation,...
CGTN: Hainan Free Trade Port: A key gateway for China's high-level opening up
A month before the official launch of China's Hainan Free Trade Port island-wide special customs operations on December 18, CGTN published an article explaining what the new customs operations mean. It highlights this landmark step as a key...
The 138th Canton Fair Boosts Global Exposure for Specialized Materials and Chemical Products
GUANGZHOU, China, Oct. 29, 2025 /PRNewswire/ -- The 138th Canton Fair is drawing attention to the rapidly advancing field of new materials and chemical products. This highly specialized exhibition section attracts buyers with clear objectives who...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ --...
Farizon SV Combi Released in Hong Kong and First Batch of 1,000 Taxis Delivered
HONG KONG, June 13, 2025 /PRNewswire/ -- Farizon New Energy Commercial Vehicle showcased multiple models at the Geely Holding Group exhibition booth during the 2025 International Automotive & Supply Chain Expo (Hong Kong), and held the...
DeepL first to deploy NVIDIA DGX SuperPOD with DGX GB200 systems in Europe, advancing Language AI with powerful generative features and enhanced user experience
DeepL's Language AI platform can now translate the entire web into another language in just 18.5 days – down from 194 days PARIS, June 11, 2025 /PRNewswire/ -- DeepL, a leading global Language AI company, today announced the deployment of an NVIDIA...